Zihao Fan

Zihao Fan

Auto-generated profile, based on publicly available information

Zihao Fan


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2023 in Emerging Microbes & Infections
Verified
Journal Article
Open access
YTYuan Tian
Yuan Tian
ZFZihao Fan
Zihao Fan
LXLing Xu
Ling Xu
YCYaling Cao
Yaling Cao
SCSisi Chen
Sisi Chen
FRFeng Ren
Feng Ren
The WHO declared to eliminate hepatitis B virus (HBV) by 2030. However, an increasing number of patients are presenting with low-level viremia (LLV) with the widespread use of antiviral medications...

6 November 2023 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Open access
YCYaling Cao
Yaling Cao
YTYuan Tian
Yuan Tian
JHJing Huang
Jing Huang
LXLing Xu
Ling Xu
ZFZihao Fan
Zihao Fan
FRFeng Ren
Feng Ren
Carbapenem-resistant Klebsiella pneumoniae (CRKP) is capable of causing serious community and hospital-acquired infections. However, currently, the identification of CRKP is complex and inefficient. Hence, this study aimed to develop methods for the early and effective identification of CRKP to allow reasonable antimicrobial therapy in a timely manner. K. pneumoniae (KP)-, K. pneumoniae carbapenemase (KPC)- and New Delhi metallo-β-lactamase (NDM)- specific CRISPR RNAs (crRNAs), polymerase chain reaction (PCR) primers and recombinase-aided amplification (RAA) primers were designed and screened in conserved sequence regions. We established fluorescence and lateral flow strip assays based on CRISPR/Cas13a combined with PCR and RAA, respectively, to assist in the detection of CRKP. Sixty-one clinical strains (including 51 CRKP strains and 10 carbapenem-sensitive strains) were collected for clinical validation. Using the PCR-CRISPR assay, the limit of detection (LOD) for KP and the blaKPC and blaNDM genes reached 1 copy/μL with the fluorescence signal readout. Using the RAA-CRISPR assay, the LOD could reach 101 copies/μL with both the fluorescence signal readout and the lateral flow strip readout. Additionally, the positivity rates of CRKP-positive samples detected by the PCR/RAA-CRISPR fluorescence and RAA-CRISPR lateral flow strip methods was 92.16% (47/51). The sensitivity and specificity reached 100% for KP and blaKPC and blaNDM gene detection. For detection in a simulated environmental sample, 1 CFU/cm2 KP could be detected. We established PCR/RAA-CRISPR assays for the detection of blaKPC and blaNDM carbapenemase genes, as well as KP, to facilitate the detection of CRKP.

17 March 2022 in Hepatology International
Verified
Journal Article
Open access
PDF file
XZXiangying Zhang
Xiangying Zhang
YTYuan Tian
Yuan Tian
LXLing Xu
Ling Xu
ZFZihao Fan
Zihao Fan
YCYaling Cao
Yaling Cao
FRFeng Ren
Feng Ren
Background and aims: The formation of an intranuclear pool of covalently closed circular DNA (cccDNA) in the liver is the main cause of persistent hepatitis B virus (HBV) infection. Here, we established highly sensitive and specific methods to detect cccDNA based on CRISPR-Cas13a technology. Methods: We used plasmid-safe ATP-dependent DNase (PSAD) enzymes and HindIII to digest loose circle rcDNA and double-stranded linear DNA, amplify specific HBV cccDNA fragments by rolling circle amplification (RCA) and PCR, and detect the target gene using CRISPR-Cas13a technology. The CRISPR-Cas13a-based assay for the detection of cccDNA was further clinically validated using HBV-related liver tissues, plasma, whole blood and peripheral blood mononuclear cells (PBMCs). Results: Based on the sample pretreatment step, the amplification step and the detection step, we established a new CRISPR-Cas13a-based assay for the detection of cccDNA. After the amplification of RCA and PCR, 1 copy/μl HBV cccDNA could be detected by CRISPR/Cas13-assisted fluorescence readout. We used ddPCR, qPCR, RCA-qPCR, PCR-CRISPR and RCA-PCR-CRISPR methods to detect 20, 4, 18, 14 and 29 positive samples in liver tissue samples from 40 HBV-related patients, respectively. HBV cccDNA was almost completely undetected in the 20 blood samples of HBV patients (including plasma, whole blood and PBMCs) by the above 5 methods. Conclusions: We developed a novel CRISPR-based assay for the highly sensitive and specific detection of HBV cccDNA, presenting a promising alternative for accurate detection of HBV infection, antiviral therapy evaluation and treatment guidance.

29 November 2022 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
SCSisi Chen
Sisi Chen
FRFeng Ren
Feng Ren
XHXiaojie Huang
Xiaojie Huang
LXLing Xu
Ling Xu
YGYao Gao
Yao Gao
MLMei Liu
Mei Liu
Background: Hepatitis delta virus (HDV) is a satellite RNA virus that relies on hepatitis B virus (HBV) for transmission. HIV/HBV/HDV coinfection or triple infection is common and has a worse prognosis than monoinfection. Objective: We aimed to reveal the epidemiological characteristics of HIV/HBV/HDV triple infection in the global population. Methods: A systematic literature search in PubMed, Embase, and the Cochrane Library was performed for studies of the prevalence of HIV/HBV/HDV triple infection published from January 1, 1990, to May 31, 2021. The Der Simonian-Laird random effects model was used to calculate the pooled prevalence. Results: We included 14 studies with 11,852 participants. The pooled triple infection rate in the global population was 7.4% (877/11,852; 95% CI 0.73%-29.59%). The results of the subgroup analysis showed that the prevalence of triple infection was significantly higher in the Asian population (214/986, 21.4%; 95% CI 7.1%-35.8%), in men (212/5579, 3.8%; 95% CI 2.5%-5.2%), and in men who have sex with men (216/2734, 7.9%; 95% CI 4.3%-11.4%). In addition, compared with people living with HIV, the HIV/HBV/HDV triple infection rate was higher in people with hepatitis B. Conclusions: This meta-analysis suggests that the prevalence of HIV/HBV/HDV triple infection in the global population is underestimated, and we should focus more effort on the prevention and control of HIV/HBV/HDV triple infection. Trial Registration: PROSPERO CRD42021273949; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=273949

8 June 2022 in Clinical and Translational Gastroenterology
Verified
Journal Article
Open access
LXLing Xu
Ling Xu
XZXiangying Zhang
Xiangying Zhang
YCYaling Cao
Yaling Cao
ZFZihao Fan
Zihao Fan
YTYuan Tian
Yuan Tian
FRFeng Ren
Feng Ren
INTRODUCTION: Hepatitis delta virus (HDV) far exceeds our expected level. There remains a lack of reliable quantitative assays for HDV RNA detection. We sought to develop a new method based on digital droplet polymerase chain reaction (ddPCR) for HDV quantitative detection. METHODS: With plasmid (pMD19T) containing HDV full genome, we determined the method for ddPCR-based HDV RNA quantification. To compare various assays for HDV detection, 30 cases diagnosed with hepatitis D and 14 controls were examined using enzyme-linked immunosorbent assay, reverse-transcriptase PCR (RT-PCR), and ddPCR. A total of 728 hepatitis B virus–related patients, including 182 patients with chronic hepatitis B, 182 with liver cirrhosis, 182 with hepatocellular carcinoma, and 182 with liver failure, were screened for HDV infection. RESULTS: The detection limit of ddPCR for HDV is significantly low, with lower limit of detection and lower limit of quantitation of 0.29 IU/mL (95% confidence interval: 1.93 × 10−3–1.22 IU/mL) and 8.76 IU/mL (95% confidence interval: 1.83–1.03 × 106 IU/mL), respectively. Among the 44 samples, the enzyme-linked immunosorbent assay detected 30 cases positive, ddPCR reported 24 samples, and RT-PCR reported 10 samples positive for HDV RNA. Moreover, the positive rates of anti-HDV were 1.1%, 3.3%, 2.7%, and 7.1% in patients with chronic hepatitis B, liver cirrhosis, hepatocellular carcinoma, and liver failure, respectively; the detection rates of RT-PCR in HDV RNA were 0%, 16.67%, 15.4%, and 20%, respectively. However, the detection rates of ddPCR were 0%, 33.33%, 30.77%, and 60%, respectively. DISCUSSION: We establish a high sensitivity and specificity quantitative HDV RNA detection method based on ddPCR. Hepatitis B virus–related end-stage liver diseases, especially liver failure, are associated with a remarkably high rate of HDV infection.

20 December 2024 in Journal of Medical Virology
Verified
Journal Article
Open access
ZFZihao Fan
Zihao Fan
LXLing Xu
Ling Xu
YCYaling Cao
Yaling Cao
TLTianxu Liu
Tianxu Liu
YTYuan Tian
Yuan Tian
FRFeng Ren
Feng Ren
Hepatitis E virus (HEV) poses a serious threat to both public health and animal food safety, thereby highlighting the demands for rapid, sensitive, and easy‐to‐use detection. This study aimed to develop a One‐Pot assay using CRISPR/Cas13a for detecting HEV RNA, suitable for point‐of‐care testing (POCT) in resource‐limited settings. CRISPR/Cas13a combined with reverse transcription polymerase chain reaction (RT‐PCR) and reverse transcription recombinase‐aided amplification (RT‐RAA) was applied to a One‐Pot assay device. Additionally, a large cohort of HEV‐infected patient (154) and animal (104) specimens was utilized for validation. The RT‐PCR/RT‐RAA + CRISPR/Cas13a assays for HEV RNA detection (genotypes: HEV‐1, HEV‐3, and HEV‐4) were established, optimized, and validated, achieving a limit of detection (LoD) of 1 copy/μL and 100% specificity. In the application validation for HEV infection, the positive rates of the RT‐PCR + CRISPR and RT‐RAA + CRISPR assays were 98.6% and 89.6% for patients, and 96.6% and 88.8% for animals, respectively, which were superior to those of RT‐qPCR. Furthermore, sample rapid lysis, reagent lyophilization, and the One‐Pot device were integrated to construct a One‐Pot assay with an LoD of 102 copies/μL. Despite slight decreases in sensitivity, the One‐Pot assay significantly reduces the assay time to 35 min, making it easy to perform, minimizing contamination, and meeting the requirements for screening. We developed a One‐Pot assay of HEV RNA using the CRISPR/Cas13a which effectively realizes a POCT test and maximizes the impetus for POCT implementation and shows potential as a valuable tool for detecting and monitoring HEV infection.